Clinical Trial: NCT03372057
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | SecuraBio |
| Information Provided By: | SecuraBio |
| Last Update Posted: | 2025-03-07 |
Study Overview
Brief Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Official Title
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Conditions
Peripheral T-cell Lymphoma
Intervention / Treatment
- Drug: Duvelisib
- Drug: Duvelisib
- Drug: Duvelisib
Other Study ID Numbers
- VS-0145-225
- 2019-001123-13
- 2019
Start Date (Actual)
2018-02-22
Primary Completion Date (Actual)
2023-12-22
Study Completion Date (Actual)
2023-12-22
Enrollment (Actual)
156
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | SecuraBio |
| Information Provided By: | SecuraBio |
| Last Update Posted: | 2025-03-07 |
Study Overview
Brief Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Official Title
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Conditions
Peripheral T-cell Lymphoma
Intervention / Treatment
- Drug: Duvelisib
- Drug: Duvelisib
- Drug: Duvelisib
Other Study ID Numbers
- VS-0145-225
- 2019-001123-13
- 2019
Start Date (Actual)
2018-02-22
Primary Completion Date (Actual)
2023-12-22
Study Completion Date (Actual)
2023-12-22
Enrollment (Actual)
156
Study Type
Interventional
Phase
Phase 2